Our People

The Right Expertise.
Financial. Operational. Clinical.

Between our team, venture partners, and board members: over 10 exits with $10bn+ in shareholder value created since 2010.

[ Leadership ] Partners

Youssef Sebban

Managing Partner

Dr. Victoria Manax Rutson, MD

General Partner

Karim Maasarani

General Partner

[ Investment ] Team

Dr. Michael Salako, PhD

Principal

Waez Umer, MD

Investment Analyst

Allison Hood

Investment Associate

Jason Criscione, PhD

Operating Partner

Alejandro Sanchez

Partner, Investments

Paul Enever, PhD

Partner, Investments

[ Operations ] Platform

Ryan Green

COO & Head of Investor Relations

Jonny He

CFO

Elaine Pang

Head of Portfolio Operations

Our venture partners and advisory board bring decades of operational leadership, clinical expertise, and institutional relationships across global healthcare markets.

[ Venture ] Partners

Peter Cicala, JD

Former Chief Patent Counsel, Celgene ($74B BMS acquisition)

Linda Li, CFA

Partner, Cleveland Clinic Ventures

Peter Greaney, MD

Founder & Executive Chairman, WorkCare

Gertjan Bartlema

CEO, Vico Therapeutics | Co-Founder, Populus Bio

Larry Florin

CEO, Hesperos | Human-on-a-Chip Technology

Dr. Dee Athwal, PhD

CEO, Complement Therapeutics | Adviser, Inflexion PE

Dr. Richard Pasternak, MD

Former VP Clinical Research, Merck & Co.

Lokman Ouijdani

International Healthcare M&A | EMEA Strategy

Dr. Abderrahim Mahfoudi, PhD

Biotech R&D Executive | Translational Research

Prof. Michael Rossbach, PhD

Genomics & Precision Medicine | Genome Institute of Singapore

Frederic Gilg

Healthcare PE & Strategy | Board Member, GA Partners

Daniel Vial

Healthcare Policy & Market Access | European Markets

[ Advisory ] Board

Francois Sarkozy, MD

Global Health Strategist | Former Government Advisor

Tom Schoenherr

Former CEO, Ambry Genetics ($600M exit to Tempus AI)

Dr. Diane Simeone, MD

Director, Moores Cancer Center, UC San Diego Health

Hocine Sidi-Said

Co-Founder & CEO, KELIX bio (acquired by Mubadala)

Dr. Manuel Hidalgo Medina, MD, PhD

Chief, Hematology & Oncology, Weill Cornell | Board, BMS & Guardant

Dr. John Hood, PhD

Founder, Impact Biomedicines ($7B Celgene acquisition) | CEO, Endeavor BioMedicines

The Right Expertise.Financial. Operational. Clinical.